JP2020524524A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524524A5
JP2020524524A5 JP2020516379A JP2020516379A JP2020524524A5 JP 2020524524 A5 JP2020524524 A5 JP 2020524524A5 JP 2020516379 A JP2020516379 A JP 2020516379A JP 2020516379 A JP2020516379 A JP 2020516379A JP 2020524524 A5 JP2020524524 A5 JP 2020524524A5
Authority
JP
Japan
Prior art keywords
cflar
hla
expression level
melanoma
normalized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020516379A
Other languages
English (en)
Japanese (ja)
Other versions
JP7227964B2 (ja
JP2020524524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033658 external-priority patent/WO2018217627A1/en
Publication of JP2020524524A publication Critical patent/JP2020524524A/ja
Publication of JP2020524524A5 publication Critical patent/JP2020524524A5/ja
Application granted granted Critical
Publication of JP7227964B2 publication Critical patent/JP7227964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020516379A 2017-05-25 2018-05-21 黒色腫の検出方法 Active JP7227964B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
US62/511,058 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (3)

Publication Number Publication Date
JP2020524524A JP2020524524A (ja) 2020-08-20
JP2020524524A5 true JP2020524524A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7227964B2 JP7227964B2 (ja) 2023-02-22

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516379A Active JP7227964B2 (ja) 2017-05-25 2018-05-21 黒色腫の検出方法

Country Status (13)

Country Link
US (3) US20180340934A1 (cg-RX-API-DMAC7.html)
EP (1) EP3631017B1 (cg-RX-API-DMAC7.html)
JP (1) JP7227964B2 (cg-RX-API-DMAC7.html)
KR (1) KR102763004B1 (cg-RX-API-DMAC7.html)
CN (1) CN111315897B (cg-RX-API-DMAC7.html)
AU (1) AU2018273844B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019024481A2 (cg-RX-API-DMAC7.html)
DK (1) DK3631017T3 (cg-RX-API-DMAC7.html)
ES (1) ES2920288T3 (cg-RX-API-DMAC7.html)
IL (1) IL270787B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019014026A (cg-RX-API-DMAC7.html)
PL (1) PL3631017T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018217627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014026A (es) 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006203830A1 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
WO2008031041A2 (en) * 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
NZ576428A (en) * 2006-11-03 2012-04-27 Baylor Res Inst Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
EP2092075A2 (en) 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
CN102667484A (zh) * 2009-10-13 2012-09-12 约翰·霍普金斯大学 识别黑素瘤肿瘤细胞的生物标记
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2014008270A1 (en) * 2012-07-03 2014-01-09 Ratiopharm Gmbh Solid state form of vemurafenib choline salt
US10407730B2 (en) * 2014-09-15 2019-09-10 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
MX2019014026A (es) 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.

Similar Documents

Publication Publication Date Title
US20220396842A1 (en) Method for using gene expression to determine prognosis of prostate cancer
EP3189156B1 (en) Thyroid cancer diagnosis by dna methylation analysis
JP5415963B2 (ja) 新しい癌マーカー
JP7111630B2 (ja) 炎症性腸疾患用のバイオマーカー
JP2017528164A5 (cg-RX-API-DMAC7.html)
JP2018524972A (ja) 肺癌の診断または検出のための方法及び組成物
JP2021514624A5 (cg-RX-API-DMAC7.html)
JP2017060515A (ja) 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法
JP2024523848A (ja) 癌検出方法、キットおよびシステム
US20210277479A1 (en) Risk scores based on human phosphodiesterase 4 d variant 7 expression
JP2021511057A5 (cg-RX-API-DMAC7.html)
CA2989480C (en) Kit and method for the diagnosis/prognosis of idiopathic scoliosis
CN107858434B (zh) lncRNA在肝癌诊断以及预后预测中的应用
HK1253908A1 (en) Method for the diagnosis/prognosis of adolescent idiopathic scoliosis
JP2020528274A5 (cg-RX-API-DMAC7.html)
JP7084034B2 (ja) 神経芽腫の微小残存病変を評価するために用いられる試薬、およびそれを用いた生体試料の分析方法
CN104498495A (zh) 前列腺癌标志物lncRNA MALAT-1及其应用
JP2019512212A (ja) 活動性結核を検出するための方法
JP2017529094A5 (cg-RX-API-DMAC7.html)
WO2017102902A1 (en) Micrornas as predictive biomarkers of type 1 diabetes
IL317236A (en) Predicting peptide receptor radiotherapy using gene expression testing
CN111315897B (zh) 用于黑素瘤检测的方法
JP2024170603A (ja) 免疫チェックポイント阻害療法からの利益を予測する方法
JP2026510430A (ja) がん診断モデルを開発する方法及びがん検出方法の開発におけるその使用
US20170130277A1 (en) Biomarker for colorectal cancer